Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Equity Average (2019 - 2025)

Historic Equity Average for TransMedics (TMDX) over the last 7 years, with Q3 2025 value amounting to $336.7 million.

  • TransMedics' Equity Average rose 6840.36% to $336.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $336.7 million, marking a year-over-year increase of 6840.36%. This contributed to the annual value of $182.9 million for FY2024, which is 1270.21% up from last year.
  • As of Q3 2025, TransMedics' Equity Average stood at $336.7 million, which was up 6840.36% from $292.2 million recorded in Q2 2025.
  • TransMedics' 5-year Equity Average high stood at $336.7 million for Q3 2025, and its period low was $55.4 million during Q2 2022.
  • Over the past 5 years, TransMedics' median Equity Average value was $148.3 million (recorded in 2024), while the average stood at $159.1 million.
  • As far as peak fluctuations go, TransMedics' Equity Average plummeted by 4062.46% in 2022, and later skyrocketed by 20482.82% in 2023.
  • TransMedics' Equity Average (Quarter) stood at $73.2 million in 2021, then surged by 156.3% to $187.6 million in 2022, then decreased by 29.73% to $131.8 million in 2023, then skyrocketed by 66.32% to $219.3 million in 2024, then soared by 53.54% to $336.7 million in 2025.
  • Its last three reported values are $336.7 million in Q3 2025, $292.2 million for Q2 2025, and $247.5 million during Q1 2025.